Deep Genomics is a pioneering company that is revolutionizing the field of drug discovery and development. Based in Toronto, this innovative company is harnessing the power of artificial intelligence to untangle the complexity of RNA biology and identify novel targets for therapeutic intervention.

The company’s proprietary AI Workbench is a game-changer in the industry. It evaluates thousands of possibilities to identify the best therapeutic candidates, making standard approaches to drug discovery seem slow and costly in comparison. The AI Workbench has already unlocked numerous targets where RNA splicing was the defect and the mechanism for correction.

Deep Genomics’ groundbreaking work doesn’t stop there. They have introduced an innovative AI foundation model called BigRNA. This transformative model, based on deep learning, represents a significant leap forward in the discovery of RNA biology and therapeutics.

In 2021, Deep Genomics successfully used its AI drug discovery platform to identify its first therapeutic candidate, a therapy for Wilson disease. This marked a significant milestone as it was the first-ever AI-discovered drug candidate.